• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

ORAOV1 Polyklonaler Antikörper

ORAOV1 Polyklonal Antikörper für IP, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

IP, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 32706-1-PBS

Synonyme

CIAB1, LTO1, Oral cancer-overexpressed protein 1, Protein LTO1 homolog, TAOS1

Filter:
  • Immunoprecipitation (IP) experiment of A431 cells using ORAOV1 Polyclonal antibody (32706-1-AP)

    IP experiment of A431 using 32706-1-AP (same clone as 32706-1-PBS)

    IP result of anti-ORAOV1 (IP:32706-1-AP, 4ug; Detection:32706-1-AP 1:500) with A431 cells lysate 1120 ug. This data was developed using the same antibody clone with 32706-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

32706-1-PBS bindet in IP, Indirect ELISA ORAOV1 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen ORAOV1 fusion protein Ag38523
Vollständiger Name oral cancer overexpressed 1
Berechnetes Molekulargewicht15kDa，137aa
Beobachtetes Molekulargewicht16 kDa
GenBank-ZugangsnummerNM_153451.2
Gene symbol ORAOV1
Gene ID (NCBI) 220064
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

ORAOV1 (oral cancer overexpressed 1) is a candidate proto-oncogene that is frequently amplified and overexpressed in various human squamous cell carcinomas (SCCs), including oral, esophageal, and cervical cancers. In cervical cancer, silencing of ORAOV1 significantly inhibits the growth of HeLa cells by causing S-phase cell cycle arrest and activating apoptosis. Additionally, ORAOV1 is overexpressed in a variety of solid tumors and may promote tumor development by preventing ribosomal damage induced by reactive oxygen species (ROS). Therefore, ORAOV1 is not only an important tumor biomarker but also a potential therapeutic target for multiple cancers.